CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,142 | -27.7% | 5,503,498 | +5.3% | 0.02% | -21.7% |
| Q2 2023 | $166,097 | +41.9% | 5,224,800 | +8.9% | 0.02% | +27.8% |
| Q1 2023 | $117,066 | -22.7% | 4,799,707 | -0.1% | 0.02% | -25.0% |
| Q4 2022 | $151,537 | -99.9% | 4,804,594 | +0.7% | 0.02% | +9.1% |
| Q3 2022 | $134,775,000 | -19.0% | 4,769,074 | -24.3% | 0.02% | +4.8% |
| Q2 2022 | $166,464,000 | -26.6% | 6,295,908 | -2.8% | 0.02% | -8.7% |
| Q1 2022 | $226,795,000 | +16.6% | 6,478,010 | +8.0% | 0.02% | +27.8% |
| Q4 2021 | $194,550,000 | +12.9% | 6,000,922 | +2.7% | 0.02% | +12.5% |
| Q3 2021 | $172,302,000 | +102.1% | 5,840,731 | +75.5% | 0.02% | +100.0% |
| Q2 2021 | $85,248,000 | +82.6% | 3,327,411 | -2.1% | 0.01% | +60.0% |
| Q1 2021 | $46,680,000 | -13.6% | 3,399,888 | +0.2% | 0.01% | -16.7% |
| Q4 2020 | $54,003,000 | – | 3,392,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |